The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients-Reference-Cited by-同舟云学术

The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients

Published:2019-02-22 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Pavo Noemi,Arfsten Henrike,Cho Anna,Goliasch Georg,Bartko Philipp E.,Wurm Raphael^ORCID,Freitag Claudia,Gisslinger Heinz,Kornek Gabriela,Strunk Guido,Raderer Markus^ORCID,Zielinski Christoph,Hülsmann Martin

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-38867-2.pdf

Reference40 articles.

1. McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371, 993–1004, https://doi.org/10.1056/NEJMoa1409077 (2014).

2. Ponikowski, P. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37, 2129–2200, https://doi.org/10.1093/eurheartj/ehw128 (2016).

3. Goliasch, G. et al. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail 18, 89–93, https://doi.org/10.1002/ejhf.435 (2016).

4. Bayes-Genis, A. et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol 65, 657–665, https://doi.org/10.1016/j.jacc.2014.11.048 (2015).

5. Zamorano, J. L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 19, 9–42, https://doi.org/10.1002/ejhf.654 (2017).

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma;Journal of Biomolecular Structure and Dynamics;2024-04-30

2. ADAM10 and Neprilysin level decreases in immune cells of mice bearing metastatic breast carcinoma: Possible role in cancer inflammatory response;International Immunopharmacology;2024-01

3. Genetic variants in the renin-angiotensin-aldosterone system: Impact on cancer risk, prognosis, and therapeutic directions;Vitamins and Hormones;2024

4. Increased Expression of Neprilysin Is Associated with Inflammation in Preeclampsia;Reproductive Sciences;2023-12-19

5. Increased expression of Neprilysin is associated with inflammation in Preeclampsia;2023-05-26